<p>在 2026 年 3 月，全球市场正面临复杂的局面，受到中东地缘政治紧张局势和波动的能源价格影响，主要指数表现不一。尽管大盘股面临压力，小盘和中盘指数如标普中盘 400 和罗素 2000 却展现出韧性，为寻求未被发现的投资机会的投资者提供了潜在机会。在这样的环境中，识别具有强大基本面的股票，以应对经济不确定性，对于长期增长潜力至关重要。</p>
<h3>全球十大未被发现的强基本面股票</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>亚洲码头</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品国际控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>达芬国际控股</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN 科技</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino 控股</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>风吟和控股</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo 集团</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>阿联酋 GO 电信</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球未被发现的强基本面股票筛选器中的 3100 只股票的完整列表。</p>
<p>下面我们展示了一些通过我们筛选的股票。</p>
<h2>Aurisco 制药有限公司 (SHSE:605116)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aurisco 制药有限公司专注于特殊复杂活性药物成分（API）、药物中间体和制剂的全球研究、开发、生产和销售，市值为 108.5 亿人民币。</p>
<p><strong>运营：</strong> Aurisco 的收入主要来自复杂活性药物成分（API）、药物中间体和制剂的销售。公司的市值为 108.5 亿人民币。</p>
<p>Aurisco 制药作为制药行业的小型企业，展现出强健的财务健康，负债权益比在五年内上升至 37.7%，但其利息支付由 EBIT 覆盖 33 倍。公司拥有高质量的盈利，去年盈利增长达到 24.6%，超过行业平均水平的 8.1%。其市盈率为 28.1 倍，而中国市场的平均市盈率为 45.2 倍，显示出良好的价值潜力。最近，Aurisco 完成了一项股票回购计划，回购超过 200 万股，金额为 6000 万人民币，截至今年 1 月初。</p>
<ul>
<li>通过我们的综合健康报告深入了解 Aurisco 制药有限公司的复杂情况。</li>
<li>通过访问我们的历史表现报告评估 Aurisco 制药有限公司的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 3 月的 SHSE:605116 负债权益比</p>
<h2>青岛新光束科技有限公司 (SHSE:688677)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 青岛新光束科技有限公司专注于全球医疗内窥镜仪器和光学产品的研究、开发、生产和销售，市值为 56.7 亿人民币。</p>
<p><strong>运营：</strong> 青岛新光束的收入主要来自内窥镜和光学相关产品的销售和维护，金额为 6.0261 亿人民币。公司的净利润率是评估其盈利能力的关键财务指标。</p>
<p>青岛新光束科技作为科技领域的灵活参与者，展现出良好的前景，其市盈率为 37.8 倍，远低于中国市场平均的 45.2 倍。公司在过去一年中实现了 26.8% 的强劲盈利增长，超过医疗设备行业 0.3% 的温和增长。销售额从 4.4283 亿人民币上升至 6.0261 亿人民币，净收入从 1.3535 亿人民币上升至 1.716 亿人民币，财务健康状况良好；这进一步体现在负债权益比在五年内从 15.5% 降至 11.8%，以及最近的股票回购总额约为 5899 万人民币，反映出对未来前景的信心。</p>
<ul>
<li>解锁我们对青岛新光束科技有限公司股票分析的全面见解，查看此健康报告。</li>
<li>检查青岛新光束科技有限公司的历史表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月的 SHSE:688677 盈利和收入增长</p>
<h2>山东圣阳电源有限公司 (SZSE:002580)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 山东圣阳电源有限公司致力于全球绿色能源解决方案，市值约为 72.7 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过其工业部门（包括电池）产生收入，金额约为 33.6 亿人民币。</p>
<p>山东圣阳电源有限公司作为电气行业的灵活参与者，展现出令人印象深刻的增长，去年盈利增长 15.8%，超过行业平均水平的 5.7%。公司的负债权益比在五年内略微上升，从 17.9% 上升至 19.2%，但其利息覆盖率仍然强劲，达到 EBIT 的 30 倍，表明财务健康状况良好。尽管其资本结构中存在一些杠杆担忧，但凭借高质量的盈利和 40.1 倍的市盈率低于中国市场平均的 45.2 倍，似乎在价值寻求者中处于良好位置。</p>
<ul>
<li>点击这里了解山东圣阳电源有限公司的细微差别，查看我们的详细分析健康报告。</li>
<li>通过查看我们的历史报告，了解山东圣阳电源有限公司的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002580 截至 2026 年 3 月的收益和收入增长</p>
<h2>抓住机会</h2>
<ul>
<li>点击这里更深入地查看我们 3100 家具有强大基本面的全球未被发现的优质公司名单。</li>
<li>在这些股票中有投资吗？通过使用 Simply Wall St 的投资组合提升您的管理方式，直观的工具将帮助您优化投资结果。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受免费访问涵盖每个大洲的市场情报。</li>
</ul>
<h2>对其他选项感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

美国小盘价值股 ETF - Avantis

罗素 2000 价值股指数 ETF - iShares

IWMI

<p>在 2026 年 3 月，全球市场因地缘政治紧张局势和波动的能源价格而表现不一。虽然大盘股面临压力，但小盘和中盘指数如标普 400 中盘股和罗素 2000 展现出韧性，为投资者提供了机会。一份包含强大基本面的前 10 大未被发现的潜力股名单中，包括了 Aurisco Pharmaceutical、青岛新光束科技和山东圣阳电源等公司，这些公司都展现出强健的财务健康和增长潜力。投资者被鼓励在经济不确定性中探索这些股票，以实现长期增长</p>

<p>In March 2026, global markets have been navigating a complex landscape marked by geopolitical tensions in the Middle East and fluctuating energy prices, leading to mixed performances across key indices. While large-cap stocks face pressure, small- and mid-cap indexes like the S&amp;P MidCap 400 and Russell 2000 have shown resilience, highlighting potential opportunities for investors seeking undiscovered gems. In such an environment, identifying stocks with strong fundamentals that can withstand economic uncertainties becomes crucial for long-term growth potential.</p>
<div class="lb-trans"><p>在 2026 年 3 月，全球市场正面临复杂的局面，受到中东地缘政治紧张局势和波动的能源价格影响，主要指数表现不一。尽管大盘股面临压力，小盘和中盘指数如标普中盘 400 和罗素 2000 却展现出韧性，为寻求未被发现的投资机会的投资者提供了潜在机会。在这样的环境中，识别具有强大基本面的股票，以应对经济不确定性，对于长期增长潜力至关重要。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被发现的强基本面股票</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian Terminals</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Natural Food International Holding</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daphne International Holdings</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN Technology</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino Holdings</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Fengyinhe Holdings</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo Group</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Etihad GO Telecom</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>亚洲码头</td>
<td>25.82%</td>
<td>12.05%</td>
<td>17.00%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>VICOM</td>
<td>NA</td>
<td>9.48%</td>
<td>7.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>1.08%</td>
<td>0.23%</td>
<td>18.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>自然食品国际控股</td>
<td>NA</td>
<td>8.04%</td>
<td>37.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>达芬国际控股</td>
<td>NA</td>
<td>19.20%</td>
<td>59.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ADDCN 科技</td>
<td>16.11%</td>
<td>8.80%</td>
<td>6.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palasino 控股</td>
<td>8.57%</td>
<td>4.07%</td>
<td>-18.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>风吟和控股</td>
<td>9.39%</td>
<td>53.36%</td>
<td>74.10%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Procimmo 集团</td>
<td>141.47%</td>
<td>6.84%</td>
<td>6.01%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>阿联酋 GO 电信</td>
<td>NA</td>
<td>38.31%</td>
<td>54.97%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3100 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球未被发现的强基本面股票筛选器中的 3100 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我们展示了一些通过我们筛选的股票。</p>
</div><h2>Aurisco PharmaceuticalLtd (SHSE:605116)</h2>
<div class="lb-trans"><h2>Aurisco 制药有限公司 (SHSE:605116)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aurisco Pharmaceutical Co., Ltd. is involved in the global research, development, production, and sales of special complex active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and preparations, with a market capitalization of CN¥10.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aurisco 制药有限公司专注于特殊复杂活性药物成分（API）、药物中间体和制剂的全球研究、开发、生产和销售，市值为 108.5 亿人民币。</p>
</div><p><strong>Operations:</strong> Aurisco generates revenue primarily from the sale of complex active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and preparations. The company's market capitalization is CN¥10.85 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Aurisco 的收入主要来自复杂活性药物成分（API）、药物中间体和制剂的销售。公司的市值为 108.5 亿人民币。</p>
</div><p>Aurisco Pharmaceutical, a small cap player in the pharma sector, has shown robust financial health with a debt to equity ratio climbing to 37.7% over five years, yet its interest payments are comfortably covered 33 times by EBIT. The company boasts high-quality earnings and an impressive earnings growth of 24.6% last year, outpacing the industry average of 8.1%. Its price-to-earnings ratio stands at 28.1x compared to the broader CN market's 45.2x, suggesting good value potential. Recently, Aurisco completed a share buyback program repurchasing over 2 million shares for CNY 60 million as of early January this year.</p>
<div class="lb-trans"><p>Aurisco 制药作为制药行业的小型企业，展现出强健的财务健康，负债权益比在五年内上升至 37.7%，但其利息支付由 EBIT 覆盖 33 倍。公司拥有高质量的盈利，去年盈利增长达到 24.6%，超过行业平均水平的 8.1%。其市盈率为 28.1 倍，而中国市场的平均市盈率为 45.2 倍，显示出良好的价值潜力。最近，Aurisco 完成了一项股票回购计划，回购超过 200 万股，金额为 6000 万人民币，截至今年 1 月初。</p>
</div><ul>
<li>Navigate through the intricacies of Aurisco PharmaceuticalLtd with our comprehensive health report here.</li>
<li>Evaluate Aurisco PharmaceuticalLtd's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合健康报告深入了解 Aurisco 制药有限公司的复杂情况。</li>
<li>通过访问我们的历史表现报告评估 Aurisco 制药有限公司的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/9343dee9-a005-457f-8e89-30f175b4b31c/chart/debt-equity-history-analysis"/></p>
<p>SHSE:605116 Debt to Equity as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 SHSE:605116 负债权益比</p>
</div><h2>Qingdao NovelBeam TechnologyLtd (SHSE:688677)</h2>
<div class="lb-trans"><h2>青岛新光束科技有限公司 (SHSE:688677)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Qingdao NovelBeam Technology Co., Ltd. specializes in the research, development, production, and sales of medical endoscopic instruments and optical products globally, with a market cap of CN¥5.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青岛新光束科技有限公司专注于全球医疗内窥镜仪器和光学产品的研究、开发、生产和销售，市值为 56.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Qingdao NovelBeam derives its revenue primarily from the sales and maintenance of endoscopes and optical-related products, amounting to CN¥602.61 million. The company's net profit margin is a key financial metric to consider when evaluating its profitability.</p>
<div class="lb-trans"><p><strong>运营：</strong> 青岛新光束的收入主要来自内窥镜和光学相关产品的销售和维护，金额为 6.0261 亿人民币。公司的净利润率是评估其盈利能力的关键财务指标。</p>
</div><p>Qingdao NovelBeam Technology, a nimble player in the tech space, is showing promising signs with its price-to-earnings ratio at 37.8x, well below the CN market average of 45.2x. The company has demonstrated robust earnings growth of 26.8% over the past year, outpacing the medical equipment industry’s modest increase of 0.3%. With sales climbing to CNY 602.61 million from CNY 442.83 million and net income rising to CNY 171.6 million from CNY 135.35 million year-on-year, its financial health appears strong; this is further underscored by a debt-to-equity ratio reduction from 15.5% to 11.8% over five years and recent share buybacks totaling approximately CNY 58.99 million for about a combined total of around1 .33%, reflecting confidence in future prospects.</p>
<div class="lb-trans"><p>青岛新光束科技作为科技领域的灵活参与者，展现出良好的前景，其市盈率为 37.8 倍，远低于中国市场平均的 45.2 倍。公司在过去一年中实现了 26.8% 的强劲盈利增长，超过医疗设备行业 0.3% 的温和增长。销售额从 4.4283 亿人民币上升至 6.0261 亿人民币，净收入从 1.3535 亿人民币上升至 1.716 亿人民币，财务健康状况良好；这进一步体现在负债权益比在五年内从 15.5% 降至 11.8%，以及最近的股票回购总额约为 5899 万人民币，反映出对未来前景的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Qingdao NovelBeam TechnologyLtd stock in this health report.</li>
<li>Examine Qingdao NovelBeam TechnologyLtd's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对青岛新光束科技有限公司股票分析的全面见解，查看此健康报告。</li>
<li>检查青岛新光束科技有限公司的历史表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3fe5c722-b1a8-447c-a4a4-aa4b8dea55e7/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688677 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 SHSE:688677 盈利和收入增长</p>
</div><h2>Shandong Sacred Sun Power SourcesLtd (SZSE:002580)</h2>
<div class="lb-trans"><h2>山东圣阳电源有限公司 (SZSE:002580)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Shandong Sacred Sun Power Sources Co., Ltd is engaged in providing green energy solutions globally and has a market capitalization of approximately CN¥7.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山东圣阳电源有限公司致力于全球绿色能源解决方案，市值约为 72.7 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its industrial segment, including batteries, amounting to approximately CN¥3.36 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其工业部门（包括电池）产生收入，金额约为 33.6 亿人民币。</p>
</div><p>Shandong Sacred Sun Power Sources Ltd., a nimble player in the electrical industry, has shown impressive growth with earnings rising 15.8% last year, outpacing the industry average of 5.7%. The company's debt-to-equity ratio slightly increased over five years from 17.9% to 19.2%, yet its interest coverage remains robust at 30 times EBIT, indicating strong financial health. With high-quality earnings and a price-to-earnings ratio of 40.1x below the China market average of 45.2x, it seems well-positioned for value seekers despite some leverage concerns in its capital structure.</p>
<div class="lb-trans"><p>山东圣阳电源有限公司作为电气行业的灵活参与者，展现出令人印象深刻的增长，去年盈利增长 15.8%，超过行业平均水平的 5.7%。公司的负债权益比在五年内略微上升，从 17.9% 上升至 19.2%，但其利息覆盖率仍然强劲，达到 EBIT 的 30 倍，表明财务健康状况良好。尽管其资本结构中存在一些杠杆担忧，但凭借高质量的盈利和 40.1 倍的市盈率低于中国市场平均的 45.2 倍，似乎在价值寻求者中处于良好位置。</p>
</div><ul>
<li>Click here to discover the nuances of Shandong Sacred Sun Power SourcesLtd with our detailed analytical health report.</li>
<li>Understand Shandong Sacred Sun Power SourcesLtd's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解山东圣阳电源有限公司的细微差别，查看我们的详细分析健康报告。</li>
<li>通过查看我们的历史报告，了解山东圣阳电源有限公司的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4281ccc6-9a0d-406b-8286-f95eb7e24479/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002580 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>SZSE:002580 截至 2026 年 3 月的收益和收入增长</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Take a closer look at our Global Undiscovered Gems With Strong Fundamentals list of 3100 companies by clicking here.</li>
<li>Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里更深入地查看我们 3100 家具有强大基本面的全球未被发现的优质公司名单。</li>
<li>在这些股票中有投资吗？通过使用 Simply Wall St 的投资组合提升您的管理方式，直观的工具将帮助您优化投资结果。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受免费访问涵盖每个大洲的市场情报。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>对其他选项感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

Undiscovered Gems in Global Markets for March 2026

- 全球市场受地缘局势及能源价格波动影响，主要指数表现各异。  
- 大型股面临压力，中小型股如 S&P MidCap 400 展现韧性，投资机会显现。  
- 寻找财务健康、能抗经济不确定性的股票对长期增长潜力至关重要。

2026 年 3 月全球市场中的未被发掘的潜力股